GERON CORP Stock Issued During Period, Value, Employee Benefit Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- GERON CORP stock issued during period, value, employee benefit plan for the quarter ending 2019-03-31 was $9.00K, a 10.00% decline year-over-year.
- GERON CORP stock issued during period, value, employee benefit plan for the quarter ending 2018-03-31 was $10.00K.
- GERON CORP stock issued during period, value, employee benefit plan for the quarter ending 2014-12-31 was $111.00K, a 75.76% decline year-over-year.
- GERON CORP stock issued during period, value, employee benefit plan for the quarter ending 2014-09-30 was $0.00.
- GERON CORP stock issued during period, value, employee benefit plan for fiscal 2019 was $9.00K, a 0.00% change from fiscal 2018.
- GERON CORP stock issued during period, value, employee benefit plan for fiscal 2018 was $9.00K, a 71.88% decline from fiscal 2017.
- GERON CORP stock issued during period, value, employee benefit plan for fiscal 2017 was $32.00K, a 47.54% decline from fiscal 2016.
- GERON CORP stock issued during period, value, employee benefit plan for fiscal 2016 was $61.00K, a 62.11% decline from fiscal 2015.
| Period end | Stock Issued During Period, Value, Employee Benefit Plan 3 month | Stock Issued During Period, Value, Employee Benefit Plan 12 month |
|---|---|---|
| 2019-12-31 | $9.00K 10-K · filed 2022-03-10 | |
| 2019-03-31 | $9.00K 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $9.00K 10-K · filed 2021-03-11 | |
| 2018-03-31 | $10.00K 10-Q · filed 2019-11-06 | |
| 2017-12-31 | $32.00K 10-K · filed 2020-03-12 | |
| 2016-12-31 | $61.00K 10-K · filed 2019-03-07 | |
| 2015-12-31 | $161.00K 10-K · filed 2018-03-16 | |
| 2014-12-31 | $111.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $424.00K 10-K · filed 2017-03-01 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $771.00K derived: sum of 4 quarters · filed 2016-03-10 |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $771.00K derived: sum of 4 quarters · filed 2016-03-10 |
| 2014-03-31 | $313.00K 10-Q · filed 2015-05-07 | $771.00K derived: sum of 4 quarters · filed 2016-03-10 |
| 2013-12-31 | $458.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10 | $1.30M 10-K · filed 2016-03-10 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-05 | $1.56M derived: sum of 4 quarters · filed 2015-03-11 |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $1.56M derived: sum of 4 quarters · filed 2015-03-11 |
| 2013-03-31 | $839.00K 10-Q · filed 2014-05-01 | $1.56M derived: sum of 4 quarters · filed 2015-03-11 |
| 2012-12-31 | $726.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-11 | $2.09M 10-K · filed 2015-03-11 |
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $1.75M derived: sum of 4 quarters · filed 2014-03-17 |
| 2012-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | $1.75M derived: sum of 4 quarters · filed 2014-03-17 |
| 2012-03-31 | $1.36M 10-Q · filed 2013-05-03 | |
| 2011-12-31 | $386.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-17 | $1.68M 10-K · filed 2014-03-17 |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-02 | |
| 2010-12-31 | $1.62M 10-K · filed 2013-03-15 | |
| 2009-12-31 | $1.16M 10-K · filed 2012-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |